公开(公告)号：US11267792B2

公开(公告)日：2022-03-08

申请号：US16630291

申请日：2018-07-03

申请人： NOURYON CHEMICALS INTERNATIONAL B.V.

发明人： Michiel Jozef Thomas Raaijmakers ,  Antoon Jacob Berend Ten Kate ,  Rens Veneman ,  Karl Fredrik Lake ,  Slavisa Jovic ,  Eike Nicolas Kantzer ,  Ina Ehlers ,  Rolf Krister Edvinsson ,  Björn Patrik Skansen ,  Michael Bertil Einar Sarning ,  Jenny Valborg Therese Adrian Meredith ,  Hendrik Van Dam

IPC分类号： C07D241/04 ,  C07C213/08 ,  C07D233/34 ,  C07D263/22 ,  C07D413/06 ,  C07D233/36

摘要： A process is provided for preparing ethyleneamines of the formula NH2—(C2H4—NH—)pH wherein p is at least 3, or derivatives thereof wherein one or more units —NH—C2H4—NH— may be present as a cyclic ethylene urea unit or piperazine unit or between two units —NH—C2H4—NH— a carbonyl moiety is present. The process includes reacting an ethanolamine-functional compound OH—(C2H4—NH—)qH wherein q is at least 2, an amine-functional compound NH2—(C2H4—NH—)rH wherein r is at least 1, in the presence of a carbon oxide delivering agent, wherein the molar ratio of ethanolamine-functional compound to amine-functional compound is from about 0.05:1 to about 0.7:1 and the molar ratio of carbon oxide delivering agent to amine-functional compound is higher than the molar ratio of ethanolamine-functional compound to amine-functional compound, provided that the process does not comprise reacting 3 moles of ethylenediamine (EDA) and 1 mole of AEEA (aminoethylethanolamine) in the presence of 1.65 moles of urea at 280 deg C. for 2 hours.

公开(公告)号：US10774040B1

公开(公告)日：2020-09-15

申请号：US16396820

申请日：2019-04-29

申请人： Chevron Phillips Chemical Company LP

发明人： Kenneth M. Lassen ,  Michael S. Matson ,  Daniel M. Hasenberg ,  Dave Schwierman

IPC分类号： C07C319/28 ,  C07C319/14 ,  C07C319/06 ,  B01J8/02 ,  C07D277/04 ,  B01D3/02 ,  C07D263/22 ,  C07D263/16 ,  B01D3/00

摘要： Processes for removing carbon disulfide from product streams containing a sulfide compound are performed by contacting the product stream with an alkanolamine and converting the carbon disulfide to a higher boiling point product, thereby reducing or eliminating carbon disulfide from the product stream. Subsequent removal of the higher boiling point product via distillation can lead to a purified sulfide stream with high purity.

公开(公告)号：US20200010463A1

公开(公告)日：2020-01-09

申请号：US16490958

申请日：2018-03-15

申请人： Merck Sharp & Dohme Corp.

发明人： Jing Su ,  Lihu Yang ,  Takao Suzuki

IPC分类号： C07D413/14 ,  A61P31/06 ,  A61K9/00 ,  C07D413/10 ,  C07D263/22 ,  C07D417/14

摘要： The present invention relates to oxazolidinone Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

公开(公告)号：US20190127407A1

公开(公告)日：2019-05-02

申请号：US16089730

申请日：2017-03-30

申请人： TAKASAGO INTERNATIONAL CORPORATION

发明人： Yuji NAKAYAMA ,  Naota YOKOYAMA

IPC分类号： C07F15/00 ,  B01J31/22 ,  C07D263/22

摘要： The present invention relates to: a compound as a ligand in a variety of catalytic organic synthetic reactions; a method for producing the compound; a synthetic intermediate of the compound; and a transition metal complex which has the compound as a ligand. The compound includes a compound represented by the following general formula (1A):

公开(公告)号：US09724336B2

公开(公告)日：2017-08-08

申请号：US14361371

申请日：2012-11-28

申请人： DAEWOONG PHARMACEUTICAL CO., LTD.

发明人： Jong-Wook Lee ,  Sang-Ho Lee ,  Taek-Joo Lim ,  Eun-Ji Koh

IPC分类号： A61K31/421 ,  A61K31/4178 ,  A61K31/4184 ,  C07D263/22 ,  A61K31/216 ,  A61K31/4422 ,  A61K45/06 ,  A61K31/41

CPC分类号： A61K31/421 ,  A61K31/216 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4422 ,  A61K45/06 ,  C07D263/22 ,  A61K2300/00

摘要： Provided is a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and an angiotensin II receptor blocker as active ingredients.

公开(公告)号：US20160152579A1

公开(公告)日：2016-06-02

申请号：US14904228

申请日：2014-07-11

申请人： CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) ,  SERVICIO ANDALUZ DE SALUD ,  FUNDACIÓN PÚBLICA ANDALUZA PARA LA INVESTIGACIÓN DE MÁLAGA EN BIOMEDICINA Y SALUD (FIMABIS)

发明人： Ruth Pérez Fernández ,  María Nieves Fresno López ,  José Elguero Bertolini ,  Pilar Goya Laza ,  Ana Belén Torres Zaguirre ,  Fernando Rodíguez De Fonseca ,  Francisco Javier Pavón Morón ,  Manuel Macías González ,  Miguel Romero Cuevas

IPC分类号： C07D263/22 ,  A61K8/49 ,  A61K31/421

CPC分类号： C07D263/22 ,  A61K8/49 ,  A61K31/421 ,  A61K2800/10 ,  A61Q19/00

摘要： The present invention relates to a family of differently substituted oxazolidinones and to the pharmaceutically acceptable salts, esters, prodrugs, tautomers, solvates and hydrates thereof, which show affinity for the alpha and gamma subtypes of the peroxisome proliferator-activated receptors (PPAR) and which, therefore, modulate the actions regulated by said receptors, such as inducing satiety, controlling ingestion and modulating metabolic effects, and thus are useful for the administration thereof as a pharmacological tool and as drugs for the treatment and/or prevention of metabolic diseases and cardiovascular diseases.

摘要翻译： 本发明涉及一种不同取代的恶唑烷酮族及其药学上可接受的盐，酯，前药，互变异构体，溶剂合物和水合物，其显示出对过氧化物酶体增殖物激活受体（PPAR）的α和γ亚型的亲和性， 因此，调节由所述受体调节的作用，例如诱导饱腹感，控制摄取和调节代谢作用，因此可用于作为药物作用和作为用于治疗和/或预防代谢性疾病和心血管的药物 疾病

公开(公告)号：US20160075724A1

公开(公告)日：2016-03-17

申请号：US14875438

申请日：2015-10-05

申请人： Merck Sharp & Dohme Corp.

发明人： Amjad Ali ,  Joann M. Napolitano ,  Qiaolin Deng ,  Zhijian Lu ,  Peter J. Sinclair ,  Gayle E. Hallet ,  Christopher F. Thompson ,  Nazia Quraishi ,  Cameron J. Smith ,  Julianne A. Hunt ,  Adrian A. Dowst ,  Yi-Heng Chen ,  Hong Li

IPC分类号： C07F7/10 ,  C07D413/04 ,  C07D233/32 ,  C07D417/10 ,  C07D285/06 ,  C07D207/26 ,  C07D233/52 ,  C07D413/10 ,  C07D263/22 ,  C07D401/04

CPC分类号： C07F7/10 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4168 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07D207/26 ,  C07D207/27 ,  C07D233/32 ,  C07D233/38 ,  C07D233/50 ,  C07D233/52 ,  C07D263/04 ,  C07D263/20 ,  C07D263/22 ,  C07D263/24 ,  C07D263/26 ,  C07D285/06 ,  C07D285/10 ,  C07D401/04 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/04 ,  C07D417/10

摘要： Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.

摘要翻译： 具有式I结构的化合物，包括化合物的药学上可接受的盐，是CETP抑制剂，可用于升高HDL-胆固醇，降低LDL-胆固醇，以及用于治疗或预防动脉粥样硬化。在式I化合物中，B或 R2是具有邻芳基，杂环，苯并杂环或苯并环烷基取代基的苯基，并且在5元环上的另一个位置具有直接连接到环上或连接到环上的芳族，杂环，环烷基，苯并杂环或苯并环烷基取代基 通过-CH2-。

公开(公告)号：US09273016B2

公开(公告)日：2016-03-01

申请号：US14136629

申请日：2013-12-20

申请人： Korea Institute of Industrial Technology

发明人： Yong Jin Kim ,  Vivek Mishra ,  Guang Meang Son ,  Jin Ku Cho ,  Baek Jin Kim

IPC分类号： C07D263/04 ,  C07D263/22 ,  C07C269/04 ,  C07C273/18

CPC分类号： C07D263/22 ,  C07C269/04 ,  C07C273/1836 ,  C07C2101/14 ,  C07C2601/14 ,  Y02P20/582 ,  C07C275/26 ,  C07C271/24 ,  C07C271/28 ,  C07C275/28 ,  C07C275/40

摘要： The present disclosure relates to a method for preparing a disubstituted urea and carbamate compounds simultaneously through a one-pot reaction of an amine, carbon dioxide and an alkylene oxide compound in the presence of an ionic liquid-based complex catalyst system containing indium. In accordance with the present disclosure, a disubstituted urea and carbamate compounds can be prepared simultaneously at high yield. In addition, the ionic liquid-based catalyst containing indium according to the present disclosure is economical because it can be reused several times.

摘要翻译： 本公开内容涉及通过胺，二氧化碳和烯化氧化合物在含有铟的离子液体基络合物催化剂体系存在下同时进行二取代的脲和氨基甲酸酯化合物的制备方法。 根据本公开，可以高收率同时制备二取代的脲和氨基甲酸酯化合物。 此外，根据本公开的含有铟的离子液体催化剂是经济的，因为它可以重复使用几次。

公开(公告)号：US20150322023A1

公开(公告)日：2015-11-12

申请号：US14651211

申请日：2014-01-29

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Jae Kwang LEE ,  Jung Taek OH ,  Jae Won LEE ,  Seo Hee LEE ,  Il-Hyang KIM ,  Jae Young LEE ,  Su Yeal BAE ,  Se Ra LEE ,  Yun Tae KIM

IPC分类号： C07D263/22 ,  C07D413/08 ,  C07D413/10

CPC分类号： C07D263/22 ,  C07D263/08 ,  C07D263/24 ,  C07D413/08 ,  C07D413/10

摘要： The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increases HDL-cholesterol levels and reduces LDL-cholesterol levels. Pharmaceutical compositions comprising the compounds are useful for the prevention or treatment of dyslipidemia or dyslipidemia-related diseases.

摘要翻译： 本发明提供联芳基或杂环联芳基取代的环己烯衍生物化合物，其异构体或其药学上可接受的盐。 本发明的化合物显示CETP抑制作用，其增加HDL-胆固醇水平并降低LDL-胆固醇水平。 包含该化合物的药物组合物可用于预防或治疗血脂异常或血脂异常相关疾病。

公开(公告)号：US09045444B2

公开(公告)日：2015-06-02

申请号：US14195666

申请日：2014-03-03

申请人： AbbVie Inc.

发明人： Hong Ding ,  Christopher L. Lynch ,  Xiaohong Song ,  Xilu Wang ,  Michael D. Wendt

IPC分类号： C07D451/02 ,  C07D205/04 ,  C07D207/04 ,  C07D211/20 ,  C07D213/38 ,  C07D215/12 ,  C07D231/12 ,  C07D233/06 ,  C07D239/38 ,  C07D241/04 ,  C07D249/18 ,  C07D401/10 ,  C07D295/155 ,  C07D207/06 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/16 ,  C07D207/20 ,  C07D207/24 ,  C07D207/50 ,  C07D211/14 ,  C07D211/26 ,  C07D211/34 ,  C07D211/38 ,  C07D211/42 ,  C07D211/46 ,  C07D211/48 ,  C07D211/58 ,  C07D211/62 ,  C07D211/70 ,  C07D211/72 ,  C07D213/36 ,  C07D213/42 ,  C07D213/70 ,  C07D213/74 ,  C07D213/81 ,  C07D213/82 ,  C07D231/56 ,  C07D233/61 ,  C07D233/64 ,  C07D235/08 ,  C07D239/06 ,  C07D257/04 ,  C07D261/20 ,  C07D263/12 ,  C07D263/22 ,  C07D263/58 ,  C07D265/30 ,  C07D267/10 ,  C07D273/01 ,  C07D277/36 ,  C07D277/74 ,  C07D295/185 ,  C07D295/30 ,  C07D307/14 ,  C07D307/22 ,  C07D307/81 ,  C07D309/14 ,  C07D309/20 ,  C07D317/66 ,  C07D333/20 ,  C07D333/34 ,  C07D335/02 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D409/10 ,  C07D413/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08 ,  C07D491/04 ,  C07D491/08 ,  C07D498/08 ,  C07C311/51 ,  C07D207/09 ,  C07D209/02 ,  C07D233/24 ,  C07D239/20 ,  C07D277/04 ,  C07D491/048 ,  C07D209/52 ,  C07D233/22

CPC分类号： C07D295/155 ,  C07C311/51 ,  C07D205/04 ,  C07D207/06 ,  C07D207/08 ,  C07D207/09 ,  C07D207/12 ,  C07D207/14 ,  C07D207/16 ,  C07D207/20 ,  C07D207/24 ,  C07D207/50 ,  C07D209/02 ,  C07D209/52 ,  C07D211/14 ,  C07D211/20 ,  C07D211/26 ,  C07D211/34 ,  C07D211/38 ,  C07D211/42 ,  C07D211/46 ,  C07D211/48 ,  C07D211/58 ,  C07D211/62 ,  C07D211/70 ,  C07D211/72 ,  C07D213/36 ,  C07D213/38 ,  C07D213/42 ,  C07D213/70 ,  C07D213/74 ,  C07D213/81 ,  C07D213/82 ,  C07D215/12 ,  C07D231/12 ,  C07D231/56 ,  C07D233/06 ,  C07D233/22 ,  C07D233/24 ,  C07D233/61 ,  C07D233/64 ,  C07D235/08 ,  C07D239/06 ,  C07D239/20 ,  C07D239/38 ,  C07D241/04 ,  C07D249/18 ,  C07D257/04 ,  C07D261/20 ,  C07D263/12 ,  C07D263/22 ,  C07D263/58 ,  C07D265/30 ,  C07D267/10 ,  C07D273/01 ,  C07D277/04 ,  C07D277/36 ,  C07D277/74 ,  C07D295/185 ,  C07D295/30 ,  C07D307/14 ,  C07D307/22 ,  C07D307/81 ,  C07D309/14 ,  C07D309/20 ,  C07D317/66 ,  C07D333/20 ,  C07D333/34 ,  C07D335/02 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D409/10 ,  C07D413/04 ,  C07D451/02 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08 ,  C07D491/04 ,  C07D491/048 ,  C07D491/08 ,  C07D498/08

摘要： Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

摘要翻译： 公开了抑制抗凋亡蛋白家族成员的活性的化合物，含有化合物的组合物和该化合物用于制备用于治疗疾病的药物的用途，其中发生表达一种或多种抗凋亡蛋白家族成员。